Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents
Pharma doesn’t just “own” a patent term. It engineers it.
In a world where blockbuster revenues are increasingly shaped by regulatory timing, the real competitive edge often isn’t the original patent—it’s what comes after. A new post from DrugPatentWat…
